Hematological Malignancy: Clinical Trials

4 trials for Hematological Malignancy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Unknown 4
Phase 11Unknown 1
Phase 31Unknown 1

Follow Hematological Malignancy: new trials by email Literature Review of Hematological Malignancy trials Research Report on Hematological Malignancy

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM
Thymoglobulin Injectable Product - Hematological Malignancy
Phase 2UnknownInstitut Paoli-Calmettes272024-03-312024-02-20
Clinical Study of CAR-T Technology for the Treatment of Relapsed Refractory Malignant Haematological Tumours
CAR-T cell therapy - Hematological Malignancy
Phase 2 / Phase 3UnknownShanxi Bethune Hospital302020-06-152024-02-02
Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells
Metoprolol, metoprolol, infliximab, etanercept, tocilizumab and/or other agents - Solid Tumor, Hematological Malignancy
Phase 1 / Phase 2UnknownChinese PLA General Hospital302019-09-152022-04-13
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Eltrombopag - Hematological Malignancy, Bone Marrow Failure Syndrome
Phase 2UnknownRabin Medical Center202013-01-012015-06-19

Narrower conditions

Hematologic Neoplasms (4)  ·  Bone Marrow Failure Disorders (1)  ·  Cytokine Release Syndrome (1)

Broader conditions

Hematologic Diseases (4)  ·  Hemic and Lymphatic Diseases (4)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Bone Marrow Diseases (1)  ·  Inflammation (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Shock (1)  ·  Systemic Inflammatory Response Syndrome (1)

Interventions

Etanercept (1)  ·  Immunotherapy, Adoptive (1)  ·  Infliximab (1)  ·  Metoprolol (1)  ·  eltrombopag (1)

Sponsors

Chinese PLA General Hospital (1)  ·  Institut Paoli-Calmettes (1)  ·  Rabin Medical Center (1)  ·  Shanxi Bethune Hospital (1)

Countries

China (2)  ·  Israel (1)

Top investigators

Moshe Yeshurun, MD (1)  ·  Xiaomin Zhang (1)